- - - • The UMBRELLA Trial will investigate the clinical utility of escalating immunotherapy for Cancer patients with Molecular Residual Disease after completion of standard of care treatment to improve patients' clinical outcome across a variety of solid cancers - • Immunotherapy will be decided based on circulating tumor DNA molecular residual disease testing in a randomized multicenter trial on patients with non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer, panc...

Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=312696